132 related articles for article (PubMed ID: 37952982)
41. Azacitidine maintenance in AML post induction and posttransplant.
Bewersdorf JP; Prebet T; Gowda L
Curr Opin Hematol; 2022 Mar; 29(2):84-91. PubMed ID: 35013047
[TBL] [Abstract][Full Text] [Related]
42. Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.
Donnette M; Hamimed M; Ciccolini J; Sicard G; Correard F; Farnault L; Ouafik L; Venton G; Fanciullino R
Br J Haematol; 2023 Nov; 203(4):625-636. PubMed ID: 37691342
[TBL] [Abstract][Full Text] [Related]
43. A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure.
Sartor C; Brunetti L; Audisio E; Cignetti A; Zannoni L; Cristiano G; Nanni J; Ciruolo R; Zingarelli F; Ottaviani E; Patuelli A; Bandini L; Forte D; Sciabolacci S; Cardinali V; Papayannidis C; Cavo M; Martelli MP; Curti A
Br J Haematol; 2023 Aug; 202(3):599-607. PubMed ID: 37226312
[TBL] [Abstract][Full Text] [Related]
44. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Wang ES; Montesinos P; Minden MD; Lee JH; Heuser M; Naoe T; Chou WC; Laribi K; Esteve J; Altman JK; Havelange V; Watson AM; Gambacorti-Passerini C; Patkowska E; Liu S; Wu R; Philipose N; Hill JE; Gill SC; Rich ES; Tiu RV
Blood; 2022 Oct; 140(17):1845-1857. PubMed ID: 35917453
[TBL] [Abstract][Full Text] [Related]
45. Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation.
Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Park JS
J Korean Med Sci; 2015 Oct; 30(10):1416-22. PubMed ID: 26425037
[TBL] [Abstract][Full Text] [Related]
46. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.
Huls G; Chitu DA; Havelange V; Jongen-Lavrencic M; van de Loosdrecht AA; Biemond BJ; Sinnige H; Hodossy B; Graux C; Kooy RVM; de Weerdt O; Breems D; Klein S; Kuball J; Deeren D; Terpstra W; Vekemans MC; Ossenkoppele GJ; Vellenga E; Löwenberg B;
Blood; 2019 Mar; 133(13):1457-1464. PubMed ID: 30630862
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
[TBL] [Abstract][Full Text] [Related]
48. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract][Full Text] [Related]
49. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.
Versluis J; Hazenberg CL; Passweg JR; van Putten WL; Maertens J; Biemond BJ; Theobald M; Graux C; Kuball J; Schouten HC; Pabst T; Löwenberg B; Ossenkoppele G; Vellenga E; Cornelissen JJ;
Lancet Haematol; 2015 Oct; 2(10):e427-36. PubMed ID: 26686044
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of Azacitidine in De Novo and Relapsed Acute Myeloid Leukemia: A Retrospective Comparative Study.
Gemuenden C; Benz R; Senn O; Goede JS; Manz MG; Gerber B
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):811-5. PubMed ID: 26437871
[TBL] [Abstract][Full Text] [Related]
51. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant.
Motabi IH; Ghobadi A; Liu J; Schroeder M; Abboud CN; Cashen AF; Stockler-Goldstein KE; Uy GL; Vij R; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1324-1329. PubMed ID: 27026249
[TBL] [Abstract][Full Text] [Related]
52. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
Pepe S; Scalzulli E; Colafigli G; Di Prima A; Diverio D; Mancini M; Latagliata R; Martelli M; Foà R; Breccia M
Ann Hematol; 2020 Oct; 99(10):2405-2416. PubMed ID: 32813071
[TBL] [Abstract][Full Text] [Related]
53. Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.
Vachhani P; Al Yacoub R; Miller A; Zhang F; Cronin TL; Ontiveros EP; Thompson JE; Griffiths EA; Wang ES
Leuk Res; 2018 Dec; 75():29-35. PubMed ID: 30445237
[TBL] [Abstract][Full Text] [Related]
54. Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.
Karakulska-Prystupiuk E; Drozd-Sokołowska J; Waszczuk-Gajda A; Stefaniak A; Dwilewicz-Trojaczek J; Kulikowska A; Chmarzyńska-Mróz E; Basak G; Paluszewska M; Boguradzki P; Jędrzejczak W
Transplant Proc; 2018 Sep; 50(7):2212-2217. PubMed ID: 30177138
[TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia.
Zhu J; Wu Q; Wang J; Niu T
Expert Rev Hematol; 2022 Apr; 15(4):375-382. PubMed ID: 35437111
[TBL] [Abstract][Full Text] [Related]
56. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
Cabrero M; Jabbour E; Ravandi F; Bohannan Z; Pierce S; Kantarjian HM; Garcia-Manero G
Leuk Res; 2015 May; 39(5):520-4. PubMed ID: 25828745
[TBL] [Abstract][Full Text] [Related]
57. Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome.
Guillaume T; Thépot S; Peterlin P; Ceballos P; Bourgeois AL; Garnier A; Orvain C; Giltat A; François S; Bris YL; Fronteau C; Planche L; Chevallier P
Transplant Cell Ther; 2021 Oct; 27(10):839.e1-839.e6. PubMed ID: 34224913
[TBL] [Abstract][Full Text] [Related]
58. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
Bewersdorf JP; Stahl M; Zeidan AM
Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
[TBL] [Abstract][Full Text] [Related]
59. Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.
Garcia-Manero G; Kazmierczak M; Wierzbowska A; Fong CY; Keng MK; Ballinari G; Scarci F; Adès L
Leuk Res; 2024 May; 140():107480. PubMed ID: 38499457
[TBL] [Abstract][Full Text] [Related]
60. Combination therapy with azacitidine, etoposide, and cytarabine in the treatment of elderly acute myeloid leukemia patients: A single center experience.
Onec B; Okutan H; Albayrak M; Can ES; Aslan V; Koluman BU; Kosemehmetoglu OS; Albayrak A
J Cancer Res Ther; 2018; 14(5):1105-1111. PubMed ID: 30197357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
